Abvc Pharma to spin off 15% of BioKey subsidiary
Parent company Abvc Pharma will distribute a 15% equity stake in BioKey (Cayman) to its shareholders, triggering a spin-off transaction.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day